Background We aimed to compare the efficacy of chimeric antigen receptor T (CAR-T) cell
therapy with that of autologous stem cell transplantation (auto-HSCT) in relapsed/refractory …

Autologous hematopoietic stem cell transplantation (ASCT) and chimeric antigen receptor T‐
cell therapy (CART) are salvage therapies that are utilised for treatment of relapsed or …

Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin's
lymphoma (NHL), representing 30% of all lymphoma cases. Within the first 2-3 years …

Aim: Autologous hematopoietic stem cell transplantation (ASCT) is the standard-of-care
curative treatment for relapsed or refractory diffuse large B-cell lymphoma (RR-DLBCL), but …

Background Chimeric antigen receptor T cell (CAR-T) therapy is an effective salvage
treatment in relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL), but the …

Purpose We intend to evaluate the efficacy of salvage treatments for relapsed or refractory
diffuse large B-cell lymphoma (R/R DLBCL) through meta-analysis. Materials and Methods …

The optimal salvage chemotherapy regimen (SC) for relapsed/refractory (R/R) diffuse large
B-cell lymphoma (DLBCL) prior to autologous stem cell transplant remains unclear …

Simple Summary Chimeric antigen receptor (CAR) T-cell therapies dramatically changed
the treatment strategies for relapsed/refractory diffuse large B-cell lymphoma and displaced …

Diffuse large B cell lymphoma (DLBCL) is the most prevalent subtype of non-Hodgkin
lymphoma. Although outcomes to frontline therapy are encouraging, patients who are …

OBJECTIVE: Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin
lymphoma (NHL). This study aimed to systematically evaluate the efficacy of chimeric …